Last updated on January 2020

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

Brief description of study

The primary objective of the trial is to confirm the efficacy of glepaglutide in reducing parenteral support volume in patients with short bowel syndrome.

Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.

Detailed Study Description

A Phase 3, international, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of glepaglutide subcutaneous (SC) injections in patients with short bowel syndrome (SBS).

Clinical Study Identifier: NCT03690206

Find a site near you

Start Over

CHRU de Lille

Lille, France
  Connect »